New malaria vaccine trial aims to stop recurrent fever

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Age 18-50 years, male or female. Healthy adults, as determined by medical history, physical examination, and screening laboratory tests. Able and willing to provide written informed consent prior to any study procedure. Available for the full duration of the study, including follow-up through 12 months post-challenge. Group-specific criteria: Malaria-naïve cohort: No prior malaria infection or residence in malaria-endemic areas; negative malaria serology at screening. Semi-immune cohort: Residence ≥ 5 years in a P. vivax-endemic area and documented or self-reported prior malaria exposure. Screening negative for HIV, hepatitis B surface antigen (HBsAg), and hepatitis C virus antibodies. For women of childbearing potential: Negative pregnancy test at screening and prior to each vaccination and/or CHMI. Commitment to use effective contraception (hormonal, IUD, barrier methods, or abstinence) from screening through the end of follow-up. Willingness to comply with all study procedures, including repeated blood sampling, controlled human malaria infection (CHMI), and inpatient or outpatient monitoring as required. Exclusion Criteria Previous participation in any malaria vaccine clinical trial or any controlled human malaria infection (CHMI) study. History of severe allergic reactions, including anaphylaxis, to vaccines or vaccine components such as Montanide ISA-51 VG, adjuvants, or synthetic peptides. Clinically significant acute or chronic medical conditions that may increase risk or interfere with study participation, including but not limited to: Cardiovascular disease Hepatic or renal impairment Neurological or psychiatric disorders Autoimmune diseases Hematologic abnormalities Immunodeficiency or immunosuppressive conditions Use of immunosuppressive therapies, systemic corticosteroids, antimalarial medications, or other agents that may interfere with vaccine immune responses within 30 days prior to enrollment. Receipt of immunoglobulins or blood products within 3 months prior to screening. Pregnancy or breastfeeding at screening or planned pregnancy during the study period. Participation in another clinical trial of an investigational product or device within 30 days prior to enrollment or planned participation during the study. Any clinically significant abnormality on screening laboratories, ECG, or physical examination that, in the investigator's judgment, could: Pose a safety risk, Confound study results, or Impair adherence to study procedures. Any condition or circumstance that, in the investigator's opinion, could compromise volunteer safety or the integrity of the trial.